<DOC>
	<DOCNO>NCT00632762</DOCNO>
	<brief_summary>This French national trial , conduct use double-blind , placebo-controlled , randomised design involve 7 center 80 patient sex . The primary objective trial evaluate effect interruption long term treatment ( ex . Greater 6 month ) Amantadine ( prescribe antidyskinetic ) patient suffer Parkinson disease treat Levodopa suffer mid dose dyskinesia . Secondary objective trial evaluation effect withdrawal Amantadine group patient : motor fluctuation , vigilance , apathy , fatigue , certain cognitive aspect , disappearance development undesirable side effect quality life .</brief_summary>
	<brief_title>Long-Term Effects Amantadine Parkinsonian ( AMANDYSK )</brief_title>
	<detailed_description>The trial involve participation patient period 3 month . The two group patient study : - group continue treatment Amantadine modification dosage ; - group dosage Amantadine progressively replace several day placebo ( aim avoid `` brutal '' withdrawal associate symptom hyperthermia rare case literature ) . The trial visit schedule : - weekly visit first 4 week , telephone call visit assure withdrawal Amantadine cause problem . - every 2 week week 4 week 8 , weekly telephone call visit . - telephone call 10th week follow end study visit week 12 . In event early withdrawal trial , assume patient give consent , complete end study visit perform prior recommence open label treatment Amantadine progressively increase dos ( 100mg every 3 day pre-study dose reach ) .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<criteria>Female Male Patients Idiopathic Parkinson 's disease Presenting peak dose dyskinesias levodopa therapy Patient receive Amantadine dyskinesia dose great equal 200 mg/day ( minimum dose one observe anti dyskinetic effect ) least 6 month . Patients 30 80 year age Patients report subjective amelioration dyskinesia Amantadine ( begin treatment ) Patient Mini Mental State Exam score &gt; 24 Patient present cognitive problem could impair comprehension patient participation protocol ( patient diary ) Receiving antiparkinsonian treatment stable dose least 2 month expectation treatment remain unchanged throughout course patient participation trial . Signed informed consent obtain Patient eligible social security ( specific requirement french law ) Atypical parkinsonian syndrome ( progressive supranuclear palsy , multisystem atrophy , etc ) Patient parkinsonian syndrome secondary medication Patients present dyskinesia whose severity allow insufficient margin observe aggravation follow potential withdrawal treatment ( UPDRS 32+33 &gt; 6 ) Patients receive treatment ApokinonÂ© injector pen ( unless treatment enters therapeutic schema fix hour ) Patient present dementia evolve dopaminergic psychosis Patient receive neuroleptic anticholinesterases Patients receive functional surgery Parkinsons ' Disease Patients pregnant risk Patients : ward state requirement french law ) .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Amantadine benefit</keyword>
	<keyword>Dyskinesia</keyword>
	<keyword>Parkinson 's disease</keyword>
</DOC>